iManageMyHealth and iSupportMyPatients: mobile decision support and health management apps for cancer patients and their doctors

Clinical decision support systems can play a crucial role in healthcare delivery as they promise to improve health outcomes and patient safety, reduce medical errors and costs and contribute to patient satisfaction. Used in an optimal way, they increase the quality of healthcare by proposing the right information and intervention to the right person at the right time in the healthcare delivery process. This paper reports on a specific approach to integrated clinical decision support and patient guidance in the cancer domain as proposed by the H2020 iManageCancer project. This project aims at facilitating efficient self-management and management of cancer according to the latest available clinical knowledge and the local healthcare delivery model, supporting patients and their healthcare providers in making informed decisions on treatment choices and in managing the side effects of their therapy. The iManageCancer platform is a comprehensive platform of interconnected mobile tools to empower cancer patients and to support them in the management of their disease in collaboration with their doctors. The backbone of the iManageCancer platform comprises a personal health record and the central decision support unit (CDSU). The latter offers dedicated services to the end users in combination with the apps iManageMyHealth and iSupportMyPatients. The CDSU itself is composed of the so-called Care Flow Engine (CFE) and the model repository framework (MRF). The CFE executes personalised and workflow oriented formal disease management diagrams (Care Flows). In decision points of such a Care Flow, rules that operate on actual health information of the patient decide on the treatment path that the system follows. Alternatively, the system can also invoke a predictive model of the MRF to proceed with the best treatment path in the diagram. Care Flow diagrams are designed by clinical experts with a specific graphical tool that also deploys these diagrams as executable workflows in the CFE following the Business Process Model and Notation (BPMN) standard. They are exposed as services that patients or their doctors can use in their apps in order to manage certain aspects of the cancer disease like pain, fatigue or the monitoring of chemotherapies at home. The mHealth platform for cancer patients is currently being assessed in clinical pilots in Italy and Germany and in several end-user workshops

Knowledge engineering complex decision support system in managing rheumatoid arthritis.

Background: The management of rheumatoid arthritis (RA) involves partially recursive attempts to make optimal treatment decisions that balance the risks of the treatment to the patient against the benefits of the treatment, while monitoring the patient closely for clinical response, as inferred from prior and residual disease activity, and unwanted drug effects, including abnormal laboratory findings. To the extent that this process is logical, based on best available evidence and determined by considered opinion, it should be amenable to capture within a Clinical Decision Support Systems (CDSSs). The formalisation of logical transformations and their execution by computer tools at point of patient encounter holds the promise of more efficient and consistent use of treatment rules and more reliable clinical decision making. Research Setting: The early Rheumatoid Arthritis (eRA) clinic of the Royal Adelaide Hospital (RAH) with approximately 20 RA patient visits per week, and involving 160 patients with a median duration of treatment of more than 4.5 years. Methods: The study applied a Knowledge Engineering approach to interpret the complexities of RA management, in order to implement a knowledge-based CDSS. The study utilised Knowledge Acquisition processes to elicit and explicitly define the RA management rules underpinning the development of the CDSS; the processes were (1) conducting a comprehensive literature review of RA management, (2) observing clinic consultations and (3) consulting with local clinical experts/leaders. Bayes’ Theorem and Bayes Net were used to generate models for assessing contingent probabilities of unwanted events. A questionnaire based on 16 real patient cases was developed to test the concordance agreement between CDSS generated guidance in response to real-life clinical scenarios and decisions of rheumatologists in response to the scenarios. Results: (1) Complex RA management rules were established which included (a) Rules for Changes in Dose/Agent and (b) Drug Toxicity Monitoring Rules. (2) A computer interpretable dynamic model for implementing the complex clinical guidance was found to be applicable. (3) A framework for a methotrexate (MTX) toxicity prediction model was developed, thereby allowing missing risk ratios (probabilities) to be identified. (4) Clinical decision-making processes and workflows were described. Finally, (5) a preliminary version of the CDSS which computed Rules for Changes in Dose/Agent and Drug Toxicity Monitoring Rules was implemented and tested. One hundred and twenty-eight decisions collected from the 8 participating rheumatologists established the ability of the CDSS to match decisions of clinicians accustomed to application of Rules for Changes in Dose/Agent; rheumatologists unfamiliar with the rules displayed lower concordance (0.7857 vs. 0.3929, P = 0.0027). Neither group of rheumatologists matched the performance of the CDSS in making decisions based on highly complex Drug Toxicity Monitoring Rules (0.3611 vs. 0.4167, P = 0.7215). Conclusion: The study has made important contributions to the development of a CDSS suitable for routine use in the eRA clinic setting. Knowledge Acquisition processes were used to elicit domain knowledge, and to refine, validate and articulate eRA management rules, that came to form the knowledge base of the CDSS. The development of computer interpretable guideline models underpinned the CDSS development. The alignment of CDSS guidance in response to clinical scenarios with questionnaire responses of rheumatologists familiar with and accepting of the management rules (and divergence with responses by rheumatologists not familiar with the rules) indicates that the CDSS can be used to guide toward evidence-based considered opinion. The poor correlation between CDSS generated guidance regarding out of range blood results and response of rheumatologists to questions regarding toxicity scenarios, underlines the value of computer aided guidance when decisions involve greater complexity. It also suggests the need for attention to rule development and considered opinion in this area. Discussion: Effective utilisation of extant knowledge is fundamental to knowledgebased systems in healthcare. CDSSs development for chronic disease management is a complex undertaking which is tractable using Knowledge Engineering and Knowledge Acquisition approaches coupled with modelling into computer interpretable algorithms. Complexities of drug toxicity monitoring were addressed using Bayes’ Theorem and Bayes Net for making probability based decisions under conditions of uncertainty. While for logistic reasons the system could not be developed to full implementation, preliminary analyses support the utility of the approach, both for intensifying treatment on a response contingent basis and also for complex drug toxicity monitoring. CDSSs are inherently suited to iterative refinements based on new knowledge including that arising from analyses of the data they capture during their use. This study has achieved important steps toward implementation and refinement.Thesis (Ph.D.) -- University of Adelaide, School of Medicine, 201

Precision medicine in the era of artificial intelligence: implications in chronic disease management.

Aberrant metabolism is the root cause of several serious health issues, creating a huge burden to health and leading to diminished life expectancy. A dysregulated metabolism induces the secretion of several molecules which in turn trigger the inflammatory pathway. Inflammation is the natural reaction of the immune system to a variety of stimuli, such as pathogens, damaged cells, and harmful substances. Metabolically triggered inflammation, also called metaflammation or low-grade chronic inflammation, is the consequence of a synergic interaction between the host and the exposome-a combination of environmental drivers, including diet, lifestyle, pollutants and other factors throughout the life span of an individual. Various levels of chronic inflammation are associated with several lifestyle-related diseases such as diabetes, obesity, metabolic associated fatty liver disease (MAFLD), cancers, cardiovascular disorders (CVDs), autoimmune diseases, and chronic lung diseases. Chronic diseases are a growing concern worldwide, placing a heavy burden on individuals, families, governments, and health-care systems. New strategies are needed to empower communities worldwide to prevent and treat these diseases. Precision medicine provides a model for the next generation of lifestyle modification. This will capitalize on the dynamic interaction between an individual's biology, lifestyle, behavior, and environment. The aim of precision medicine is to design and improve diagnosis, therapeutics and prognostication through the use of large complex datasets that incorporate individual gene, function, and environmental variations. The implementation of high-performance computing (HPC) and artificial intelligence (AI) can predict risks with greater accuracy based on available multidimensional clinical and biological datasets. AI-powered precision medicine provides clinicians with an opportunity to specifically tailor early interventions to each individual. In this article, we discuss the strengths and limitations of existing and evolving recent, data-driven technologies, such as AI, in preventing, treating and reversing lifestyle-related diseases

Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes

Chronic hepatitis B, a major cause of liver disease and cancer, affects over 250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative HBV therapies are underway, consisting of combinations of multiple novel agents +/- nucleos(t)ide reverse transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, and subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives and regulatory agencies. This Viewpoint outlines areas of consensus within our multi-stakeholder group for stopping finite therapies in chronic Hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, pre-defined stopping criteria, pre-defined retreatment criteria, duration of investigational therapies, and follow up after stopping therapy. Future research of unmet needs are discussed

2005

https://deepblue.lib.umich.edu/bitstream/2027.42/139344/2/objects.ziphttps://deepblue.lib.umich.edu/bitstream/2027.42/139344/4/metadata.zi

Acute kidney disease and renal recovery : consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup

Consensus definitions have been reached for both acute kidney injury (AKI) and chronic kidney disease (CKD) and these definitions are now routinely used in research and clinical practice. The KDIGO guideline defines AKI as an abrupt decrease in kidney function occurring over 7 days or less, whereas CKD is defined by the persistence of kidney disease for a period of > 90 days. AKI and CKD are increasingly recognized as related entities and in some instances probably represent a continuum of the disease process. For patients in whom pathophysiologic processes are ongoing, the term acute kidney disease (AKD) has been proposed to define the course of disease after AKI; however, definitions of AKD and strategies for the management of patients with AKD are not currently available. In this consensus statement, the Acute Disease Quality Initiative (ADQI) proposes definitions, staging criteria for AKD, and strategies for the management of affected patients. We also make recommendations for areas of future research, which aim to improve understanding of the underlying processes and improve outcomes for patients with AKD

Interventions to Support Mental Health among Those with Health Conditions that Present Risk for Severe Infection from Coronavirus Disease 2019 (COVID-19): A Scoping Review of English and Chinese-Language Literature

This study aimed to address knowledge gaps related to the prevention and management of mental health responses among those with a condition that presents risk of severe COVID-19 infection. A scoping review that mapped English and Chinese-language studies (2019–2020) located in MEDLINE (Ovid), Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycInfo, Sociological Abstracts, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Airiti Library was undertaken. Search terms related to COVID-19, mental health, and physical health were used and articles that included all three of these factors were extracted (n = 77). With the exception of one hospital-based pilot study, there were no intervention studies targeting mental health in those at risk of severe COVID-19 infection. Promising practices such as integrated care models that appropriately screen for mental health issues, address health determinants, and include use of digital resources were highlighted. Patient navigator programs, group online medical visits, peer support, and social prescribing may also support those with complex needs. Future policies need to address digital health access inequities and the implementation of multi-integrated health and social care. Furthermore, research is needed to comprehensively assess multi-integrated interventions that are resilient to public health crises.This paper is an extended version of our conference paper published in Proceedings of the 3rd International Electronic Conference on Environmental Research and Public Health—Public Health Issues in the Context of the COVID-19 Pandemic: online, 11–25 January 2021